Merck Reports Q3 Revenue of $18.1 Billion, Raises 2026 Earnings Guidance
Merck (MRK) reported Q3 2026 revenue of $18.1B, up 4% YoY, and EPS of $2.49, beating estimates. Keytruda sales rose 6% to $8.6B. Merck raised 2026 EPS guidance to $2.77-$2.82 and revenue to $66.8B-$67.3B. Shares rose 2% in premarket trading.
How this was made
The 30-second read
Why it matters
The core tradable catalyst is the raised 2026 EPS guidance and narrowed revenue range following a Q3 beat, which can drive immediate re-rating and revisions to consensus estimates.
Market read
A same-day earnings and guidance update with specific 2026 ranges is a direct input to valuation and positioning for pharma earnings season.
What to watch
Keytruda includes Qlex subcutaneous formulation sales and Winrevair’s surge; traders may want to watch for any implied margin or competitive pressure not discussed in the excerpt.
Background
Merck’s Q3 print included growth in Keytruda (including Qlex) and a sharp Winrevair increase, alongside oncology pipeline updates from ESMO.
Ticker impact
Merck reported Q3 EPS of $2.49 and revenue of $18.1B, then raised 2026 EPS guidance to $2.77-$2.82 and narrowed revenue to $66.8B-$67.3B.
Likely upward pressure as the market reprices 2026 earnings power following the raised EPS range and improved product momentum.
The article contains the company’s own fresh guidance numbers and Q3 beat details, which are direct inputs to near-term valuation and analyst model updates.
Market effects
Reinforces positive read-through for large-cap pharma earnings durability, especially oncology franchises (Keytruda) and pulmonary hypertension growth (Winrevair).
Primarily US large-cap pharma sentiment; may modestly lift broader healthcare risk appetite in premarket.
Limited direct global macro linkage, but oncology pipeline updates can influence international pharma sentiment around late-stage validation.
Counterpoint
Pipeline commentary (sac-TMT and a Phase 3 cancer vaccine) may not offset near-term valuation sensitivity if investors focus more on near-term sales trajectory than longer-dated optionality.
Key entities
- companyMerck & Co.
Reported Q3 2026 results and raised 2026 EPS guidance to $2.77-$2.82 while narrowing revenue guidance to $66.8B-$67.3B.
- productKeytruda
Q3 revenue $8.6B, up 6% YoY, including $830M from Qlex subcutaneous formulation.
- productWinrevair
Q3 revenue $694M, up 93% YoY.
- productGardasil
Q3 vaccine sales rose 14% excluding currency to about $2B.
- pipeline_assetsac-TMT
Investigational antibody-drug conjugate discussed with new data presented at ESMO.
